LORA Stock Chart & Stats
€75.50
€1.00(1.41%)
At close: 4:00 PM EDT
€75.50
€1.00(1.41%)
Day’s Range― - ―
52-Week Range€66.50 - €81.50
Previous CloseN/A
Volume0.00
Average Volume (3M)1.00
Market Cap
€199.53B
Enterprise Value€249.08K
Total Cash (Recent Filing)€4.05B
Total Debt (Recent Filing)€16.71B
Price to Earnings (P/E)32.1
Beta0.39
Next Earnings
Feb 11, 2027EPS Estimate
1.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.39
Shares Outstanding2,663,249,000
10 Day Avg. Volume0
30 Day Avg. Volume1
Financial Highlights & Ratios
PEG Ratio-4.09
Price to Book (P/B)5.57
Price to Sales (P/S)4.42
P/FCF Ratio27.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€87.06Price Target Upside15.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)2.71
Revenue Forecast (FY)€46.66B
Bulls Say, Bears Say
Bulls Say
Durable ProfitabilityConsistently high gross and operating margins indicate strong brands, pricing power and scale advantages. The record H1 margin suggests profitability remains resilient while L’Oréal continues funding innovation and marketing.
Broad-Based Revenue GrowthGrowth across divisions and regions reduces dependence on a single category or geography. Continued outperformance of the global beauty market supports L’Oréal’s competitive position and provides a durable base for future expansion.
Digital Reach And InnovationStrong e-commerce expansion improves consumer access and channel flexibility, while rising new-product contribution shows effective R&D and brand renewal. These capabilities can sustain relevance, mix improvement and long-term growth.
Bears Say
Higher Debt And Acquisition Cash UsesLeverage remains manageable, but debt increased following acquisitions and shareholder distributions. This reduces financial flexibility and could constrain investment or returns if integration costs, rates or operating conditions worsen.
Galderma Earnings DilutionThe accounting amortization is non-cash, but it will depress reported earnings and dilute the near-term contribution from the Galderma investment. This may obscure underlying performance and extend the payback period for the transaction.
Uneven Cash ConversionSolid cash generation supports reinvestment and distributions, but inconsistent conversion from operating profit points to working-capital or investment variability. Persistent volatility could reduce funding flexibility for acquisitions and shareholder returns.
LORA FAQ
What was L'Oreal’s price range in the past 12 months?
L'Oreal lowest stock price was €66.50 and its highest was €81.50 in the past 12 months.
What is L'Oreal’s market cap?
L'Oreal’s market cap is €199.53B.
When is L'Oreal’s upcoming earnings report date?
L'Oreal’s upcoming earnings report date is Feb 11, 2027 which is in 152 days.
How were L'Oreal’s earnings last quarter?
L'Oreal released its earnings results on Jul 29, 2026. The company reported €1.464 earnings per share for the quarter, missing the consensus estimate of €1.481 by -€0.017.
Is L'Oreal overvalued?
According to Wall Street analysts L'Oreal’s price is currently Undervalued.
Does L'Oreal pay dividends?
L'Oreal does not currently pay dividends.
What is L'Oreal’s EPS estimate?
L'Oreal’s EPS estimate is 1.27.
How many shares outstanding does L'Oreal have?
L'Oreal has 2,663,249,000 shares outstanding.
What happened to L'Oreal’s price movement after its last earnings report?
L'Oreal reported an EPS of €1.464 in its last earnings report, missing expectations of €1.481. Following the earnings report the stock price went up 0.685%.
Which hedge fund is a major shareholder of L'Oreal?
Currently, no hedge funds are holding shares in DE:LORA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
L'Oreal Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€87.06 (15.31% Upside)
€87.06 (15.31% Upside)
Blogger Sentiment
Neutral
DE:LORA Sentiment 50%
Sector Average 61%
Sector Average 61%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-0.69%
12-Months-Change
Fundamentals
Return on Equity
1.92%
Trailing 12-Months
Asset Growth
18.37%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
L'Oreal
L'Oréal S.A., a prominent global enterprise, specializes in the development, production, and worldwide distribution of a diverse range of cosmetic and personal care goods catering to both male and female consumers. Its business activities are structured into four key segments: Consumer Products, L'Oréal Luxe, Professional Products, and Active Cosmetics. The company's extensive product portfolio includes hair cleansing and conditioning treatments, styling aids, shower gels, various skincare formulations, facial cleansers, deodorants, sun protection items, and a broad selection of makeup and perfumes. These offerings are marketed under numerous acclaimed brands, such as L'Oréal Paris, Garnier, Maybelline, Lancôme, Kiehl's, Vichy, and La Roche-Posay, among many others. L'Oréal distributes its products through a wide array of channels, including professional hair salons, large-scale retail outlets, specialized perfumeries, department stores, pharmacies, drugstores, medispas, dedicated brand stores, travel retail locations, and via its significant e-commerce presence. Established in 1909, L'Oréal S.A. maintains its corporate headquarters in Clichy, France.
LORA Company Deck
LORA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized multiple strong operational achievements: robust adjusted like‑for‑like growth (6.5%), record operating margin (21.3%), high e‑commerce growth (18% to EUR 7.4bn), strong division and regional performance (Professional +11.6%, Derm +10.6%, SAPMENA +13.8%), and solid cash generation (operating net cash flow +13.9%). Key challenges were manageable but notable: FX headwinds (-2.8%), sizeable nonrecurring charges (-EUR 430m), heavier A&P investment (+70bps), increased net debt and cash outflows for acquisitions/dividends (free cash flow impact), and accounting/amortization dilution from the Galderma stake (USD ~450m p.a. PPA impact). Overall, the positives (broad growth, record margins, innovation and e‑commerce momentum, clear plan to keep investing) outweigh the negatives, which are largely strategic investments, timing effects and accounting impacts rather than indications of a structural earnings deterioration.View all DE:LORA earnings summariesLORA Stock 12 Month Forecast
Average Price Target
€87.06
▲(15.31% Upside)